Navigation Links
Soligenix to Host Conference Call and Webcast Discussion on Oral Mucositis
Date:10/28/2013

2;, a vaccine against anthrax exposure. RiVax™ has been shown to be well tolerated and immunogenic in two Phase 1 clinical trials in healthy volunteers. Both RiVax™ and VeloThrax™ are currently the subject of a $9.4 million National Institute of Allergy and Infectious Diseases (NIAID) grant supporting development of Soligenix's new vaccine heat stabilization technology known as ThermoVax™.  Soligenix is also developing OrbeShield™ for the treatment of gastrointestinal acute radiation syndrome (GI ARS) under BARDA and NIAID contract awards valued up to $26.3 million and $6.4 million, respectively. OrbeShield™ has previously demonstrated statistically significant preclinical survival results in a canine model of GI ARS funded by the NIAID.  Recently, Soligenix announced a worldwide exclusive collaboration with Intrexon Corporation that will focus on the joint development of a treatment for melioidosis, a high priority biothreat and an area of unmet medical need.

For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.

This press release contains forward-looking statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities, including but not limited to, potential market sizes, patient populations and clinical trial enrollment.  Statements that are not historical facts, such as "anticipates," "estimates," "believes," "intends," "potential," or similar expressions, are forward-looking statements.  These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements.  Soligenix cannot assure you that it will be able to successfully develop, achieve regulatory approval for or commercialize p
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
2. Soligenix Reports Year-End 2012 Financial Results and Highlights Recent Accomplishments
3. Soligenix Announces Collaboration with Infectious Disease Research Institute to Develop Thermostabilized Biodefense Vaccines Utilizing Novel Adjuvants
4. Soligenix Reports Year-End 2011 Financial Results and Highlights Recent Accomplishments
5. Soligenix Announces 1 for 20 Reverse-Split of its Common Stock
6. Proove Biosciences Will Be Exhibiting At The 2013 Common Sense Pain Management Conference
7. Z Trim to Present at the 2013 Clean Label Conference
8. Vet-Stem, Inc. Founder and CEO Presents at TargetMeeting’s 3rd World Drug Discovery Online Conference
9. The Conference Forum Announces the Launch of the 2nd Annual Medicaid Rebate Summit
10. Techne Corporation To Host Conference Call On October 29, 2013 To Announce First Quarter Financial Results
11. Sigma-Aldrich Announces Q3 2013 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... 2015 German-based Moenninghoff has designated the ... for the Moenninghoff product line . ... to announce that the R.M. Hoffman Company will be ... founded in 1916, this is a strategically important step. ... kind of professional distributor we need to successfully grow ...
(Date:6/1/2015)... YONGIN, South Korea , June 1, ... Green Cross Biotherapeutics Inc. (GCBT) kicked off construction today ... the Montreal Technoparc,s Saint-Laurent Campus. The CA$315 million project ... in Canada in the biopharmaceutical ... intravenous immunoglobulin (IVIG) and albumin manufacturing plant in ...
(Date:6/1/2015)... HANOVER, N.J. , June 1, 2015 /PRNewswire/ ... II clinical study of CTL019, an investigational chimeric ... its potential in the treatment of specific types ... study conducted by the University of Pennsylvania,s Perelman ... or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ...
(Date:6/1/2015)... N.C. , June 1, 2015  Fennec ... presentation of positive interim results from a poster ... multi-centre open label randomised phase III trial of ... ototoxicity in patients receiving cisplatin (Cis) monotherapy for ... at the American Society of Clinical Oncology (ASCO) ...
Breaking Biology Technology:R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 2R.M. Hoffman Company designated official United States distributor for the Moenninghoff product line. 3Green Cross Biotherapeutics Kicks Off Construction in Montreal 2Green Cross Biotherapeutics Kicks Off Construction in Montreal 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4
... for 15 minutes, couldn't imagine the influence the Internet, blogging, social ... these tools, everyone can have their 15 minutes - but just ... is about all anyone has time for these days, at least ... reminded of this after coming back from a near three-week holiday ...
... the lead cancer drug candidate of Madison's Quintessence Biosciences ... Food and Drug Aministration for being tested on cancer ... meeting of the American Association for Cancer Research , ... scale and applied in safe doses, the company announced. , ...
... Madison, Wis . - Mithridion, Inc ., a biopharmaceutical ... of Alzheimer's disease, has closed an additional $1.2 million of ... , ,The latest round of funding brings the total equity ... above the company's initial funding target. Mithridion will use the ...
Cached Biology Technology:On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Quintessence Biosciences advances cancer drug 2Alzheimer's drug developer lands $1.2M in venture funding 2Alzheimer's drug developer lands $1.2M in venture funding 3
(Date:6/1/2015)... June 1, 2015 According to ... Sensing Market by Technology (Touch-based & Touchless), Application (Consumer ... & by Geography - Global Forecast to 2020", published ... is expected to reach $23.55 Billion by 2020, at ... Browse 83 market data T ables ...
(Date:6/1/2015)... 1, 2015 According to ... Market by Application (Government, Military & Defense, Healthcare, ... and Security), Technology (Face Recognition, Fingerprint Recognition, Iris ... Recognition, and Others), Function (Contact and Non-Contact) & ... Europe , APAC, Row) - Global ...
(Date:5/29/2015)... , May 28, 2015 Research ... addition of the "Facial Recognition Market by ... - Global Forecast to 2020" report to ... have seen facial recognition technology become more efficient ... to gain traction and investment from the commercial ...
Breaking Biology News(10 mins):Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 2Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 3Gesture Recognition & Touchless Sensing Market Worth $23.55 Billion by 2020 4Next Generation Biometrics Market Worth $24,448.84 Million by 2020 2Next Generation Biometrics Market Worth $24,448.84 Million by 2020 3Next Generation Biometrics Market Worth $24,448.84 Million by 2020 4Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2
... a remote region of the Russian mountains a previously unknown ... Lead Scientist Professor Hans Cornelissen and his Russian-Dutch team describe ... root belongs to the small alpine plant Corydalis conorhiza and ... through layers of snow. Given this novel behaviour, the scientists ...
... In a study published in the open-access, peer-reviewed ... Han and Piotr Jablonski at Seoul National University, Korea, ... their genitalia from males, forceful copulatory attempts, females of ... the evolutionary arms race between the sexes. Instead, females ...
... are acclaimed in representing natural climate archives. For ... of these annual rings depend mainly on temperature and ... seasonal variations, the correlation is not so evident. ... Geosciences and their colleagues of the Australian National University ...
Cached Biology News:Newly discovered snow roots are 'evolutionary phenomenon' 2Hidden genitalia in female water striders makes males 'sing' 2Australia's climate: Drought and flooding in annual rings of tropical trees 2